What are the clinical phenotypes (subtypes) of progressive supranuclear palsy (PSP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Types of Progressive Supranuclear Palsy (PSP)

PSP encompasses multiple distinct clinical phenotypes, with the Movement Disorder Society (MDS) criteria recognizing at least 7-10 subtypes based on predominant clinical features at presentation, though Richardson's syndrome (PSP-RS) remains the most common, accounting for approximately 42-75% of cases. 1, 2, 3

Recognized PSP Subtypes

The clinical phenotypes are classified based on the predominant feature during the first 3 years after symptom onset:

Classic Presentation

  • PSP-Richardson's Syndrome (PSP-RS): The prototypical presentation featuring early postural instability with unexplained falls, vertical supranuclear gaze palsy (typically appearing later in disease course), axial dystonia, and symmetric akinetic-rigid parkinsonism that is levodopa-resistant 1. This subtype shows rapid progression with the shortest median disease duration of 5-7 years 4, 3.

Parkinsonian Variants

  • PSP-Parkinsonism (PSP-P): Characterized by asymmetric, tremor-predominant parkinsonism that may show partial levodopa responsiveness 5, 3. This subtype has the longest disease duration (8-12 years) and reaches disability milestones significantly later than other subtypes 4, 3.

  • PSP-Progressive Gait Freezing (PSP-PGF): Predominant freezing of gait as the presenting feature 2, 3.

Cortical Presentations

  • PSP-Frontal (PSP-F): Frontal/executive dysfunction predominates, with behavioral and cognitive changes preceding motor symptoms by approximately 4 years and disease duration of 9 years 2, 5.

  • PSP-Speech/Language (PSP-SL): Primary progressive aphasia or apraxia of speech as the dominant feature 2, 5.

  • PSP-Corticobasal Syndrome (PSP-CBS): Asymmetric limb rigidity, dystonia, apraxia, and cortical sensory deficits mimicking corticobasal degeneration 5, 3.

Other Subtypes

  • PSP-Postural Instability (PSP-PI): Isolated early postural instability without other prominent features 2, 3.

  • PSP-Ocular Motor Dysfunction (PSP-OM): Predominant oculomotor abnormalities (blurred vision, slow saccades) as presenting symptoms 2, 3.

  • PSP-Postural and Frontal (PSP-PF): A recently identified aggressive phenotype combining early postural instability with frontal dysfunction, showing rapid progression (6-year median duration) and high cortical and subcortical tau burden 2.

  • Rare variants: PSP-cerebellar ataxia (PSP-C) and PSP-primary lateral sclerosis (PSP-PLS) have been reported but are exceedingly uncommon 5.

Clinical Implications

The PSP-RS phenotype can be distinguished by older age at onset, akinetic-rigid levodopa-resistant parkinsonism, while cortical variants (PSP-F, PSP-SL, PSP-CBS) more commonly present with tremor and asymmetric or levodopa-responsive features 5. Subcortical variants demonstrate milder cognitive impairment compared to cortical presentations 5.

Important Caveats

  • Many patients evolve toward PSP-RS phenotype over time, with the proportion increasing from 42% at initial presentation to 75% when considering the entire disease course 6.
  • Multiple phenotypes may coexist in individual patients, requiring application of Multiple Allocation eXtinction (MAX) rules to determine the predominant subtype 6.
  • The APOEε4 allele is associated with earlier onset of parkinsonism and oculomotor dysfunction, potentially influencing phenotypic expression 5.

For prognostic counseling, PSP-P offers the most favorable trajectory with longest survival and delayed disability, while PSP-RS and the newly described PSP-PF represent the most aggressive forms with rapid progression to major disability milestones 2, 4, 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.